Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate
about
Current application of proteomics in biomarker discovery for inflammatory bowel diseaseLow dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapsesEvaluation of nephroprotective and immunomodulatory activities of antioxidants in combination with cisplatin against murine visceral leishmaniasisMinimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use.Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid?Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease.Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.Consensus guidelines for management of glycogen storage disease type 1b - European Study on Glycogen Storage Disease Type 1.Five-aminosalicylic Acid: an update for the reappraisal of an old drugSulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.Mesalazine for diverticular disease of the colon--a new role for an old drug.Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.Renal effects of long-term treatment with 5-aminosalicylic acidTherapeutic strategies for the management of ulcerative colitis.Balsalazide in treating colonic diseases.Naringin ameliorates acetic acid induced colitis through modulation of endogenous oxido-nitrosative balance and DNA damage in rats.Renal manifestations and complications of inflammatory bowel disease.Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity.Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease.Do gastroenterologists monitor their patients taking 5-amino-salicylates following initiation of treatmentTubulointerstitial nephritis: diagnosis, treatment, and monitoring.Altered IgG(4) renal clearance in patients with inflammatory bowel diseases. Evidence for a subclinical impairment of protein charge renal selectivity.What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?Expression of arylamine N-acetyltransferase in human intestineRenal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy.Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis.Beneficial effect of Amorphophallus paeoniifolius tuber on experimental ulcerative colitis in rats.Effects of co-supplementation of vitamins E and C on gentamicin-induced nephrotoxicity in rat.A new oral delivery system for 5-ASA: preliminary clinical findings for MMx.
P2860
Q28078755-CEDC2397-B0BD-4107-A762-5C720EB99D12Q28205383-62DB1184-D19E-4205-AE23-877CF39E7280Q28483086-7DFD4001-199E-4163-832B-64E7840D7849Q32026628-0C2210B2-B0CE-4B0B-95E2-C43993EC67F1Q33788444-B137EA3D-C462-4D1A-A4C3-C62BD590F0BFQ33815735-6F1DA52B-4E96-4A09-85E8-EA5C1E7D7E44Q34648896-8A90E164-6084-426C-8960-C86C59C4ACEBQ34954722-B8E4CFFB-01E5-4413-ABDA-EF371078FD89Q35061210-315D1B44-2133-4ECF-A12C-3AEAF0BCE65BQ35595076-B507A267-7ECE-4EE7-B79F-D578D86EA858Q36040685-800B15F7-1648-487F-91FA-D1D00421380DQ36055120-1FD81C64-5907-4E70-8150-5515BA586969Q37223156-21B441F8-B4BE-4D15-82E0-FD27EBCDD17BQ37318035-B4AA1CD6-2DF5-4B66-94B2-76DA1C10BCA6Q37587217-27D0C00B-9C85-4C83-BEB4-355DF9461B63Q37669820-DE5B77EA-FB5C-4C66-A654-8F6EFB24BDA7Q37789000-71CC7415-9103-4940-A9E7-EBE51A690608Q37827164-70B179EC-7998-474F-BBDA-6A6853E5B8A6Q37892884-7B13C68A-1BC3-4D49-AE8B-F6BAF1AFBE5DQ38609002-75BFEF7C-915C-41ED-B9B3-0869102911CEQ40683631-52437276-5948-4A28-967B-1B879980FA4CQ41726079-DF93F1DB-FF3F-4278-AD16-91AFDAFF5E33Q41903886-AE1CA9AE-2898-4DC1-959A-3E3D329B4740Q42261666-6D935211-AAE2-426E-A657-56EE85842B75Q43687351-EF9B7FA7-710D-4390-9C86-05BDD664DEEAQ43892494-1B858B0D-C8C2-4398-812A-4718CDF2F85DQ44486087-39F1344D-4E73-4A17-AA7C-A15479C67FE8Q46381211-10BCC3A7-2D8F-451B-863D-6392BFF26961Q46469247-F4759D58-B78B-42E1-B138-D66305020BC1
P2860
Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Renal tubular dysfunction in p ...... e treated with aminosalicylate
@ast
Renal tubular dysfunction in p ...... e treated with aminosalicylate
@en
type
label
Renal tubular dysfunction in p ...... e treated with aminosalicylate
@ast
Renal tubular dysfunction in p ...... e treated with aminosalicylate
@en
prefLabel
Renal tubular dysfunction in p ...... e treated with aminosalicylate
@ast
Renal tubular dysfunction in p ...... e treated with aminosalicylate
@en
P2093
P2860
P356
P1433
P1476
Renal tubular dysfunction in p ...... e treated with aminosalicylate
@en
P2093
Schreiber S
P2860
P304
P356
10.1136/GUT.40.6.761
P407
P577
1997-06-01T00:00:00Z